<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M700</article-id>
      <article-id pub-id-type="publisher-id">molbank-2010-M700</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>6-Phenyl-2-(4-phenyl-5-thioxo-4,5-dihydro-1<italic>H</italic>-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2<italic>H</italic>)-one</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Mishra</surname>
            <given-names>Ravinesh</given-names>
          </name>
          <xref rid="c1-molbank-2010-M700" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Siddiqui</surname>
            <given-names>Anees A.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shaharyar</surname>
            <given-names>Mohammad</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Husain</surname>
            <given-names>Asif</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rashid</surname>
            <given-names>Mohd</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2010-M700">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi-110062, India</aff>
      <author-notes>
        <corresp id="c1-molbank-2010-M700"><label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>ravi_kcp@rediffmail.com.</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>25</day>
        <month>10</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="collection"><month>12</month>
        <year>2010</year>
      </pub-date>
      <volume>2010</volume>
      <issue>4</issue>
      <elocation-id>M700</elocation-id>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>10</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>10</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2010 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2010</copyright-year>
        <license>
          <p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>6-Phenyl-2-(4-phenyl-5-thioxo-4,5-dihydro-1<italic>H</italic>-1,2,4-triazol-3-yl)-4,5-dihydro-pyridazin-3(2<italic>H</italic>)-one <bold>3</bold> has been synthesized by a sequence of reactions starting from 6-oxo-3-phenyl-5,6-dihydropyridazine-1(4<italic>H</italic>)-carbohydrazide <bold>1</bold>. The structure of the title compound <bold>3</bold> was established on the basis of IR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR and mass spectral data.</p>
      </abstract>
      <kwd-group>
        <kwd>carbohydrazide</kwd>
        <kwd>4,5-dihydro-3(2<italic>H</italic>)-pyridazinone</kwd>
        <kwd>1,2,4-triazole</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
      <p>The chemistry of 4,5-dihydro-3(2<italic>H</italic>)-pyridazinone has been an interesting field of study since decades. The synthesis of novel pyridazinone derivatives and investigation of their chemical and biological behavior have gained more importance in recent decades for biological, medicinal, and agricultural reasons. Living organisms have difficulties in the construction of N-N bonds that limits the natural abundance of compounds having such bonds. Pyridazinone derivatives, a class of compounds containing the N-N bond, exhibit a wide range of pharmacological activities such as antidepressant [<xref ref-type="bibr" rid="B1-molbank-2010-M700">1</xref>], antihypertensive [<xref ref-type="bibr" rid="B2-molbank-2010-M700">2</xref>,<xref ref-type="bibr" rid="B3-molbank-2010-M700">3</xref>], antithrombotic [<xref ref-type="bibr" rid="B4-molbank-2010-M700">4</xref>], anticonvulsant [<xref ref-type="bibr" rid="B5-molbank-2010-M700">5</xref>], cardiotonic [<xref ref-type="bibr" rid="B6-molbank-2010-M700">6</xref>], antibacterial [<xref ref-type="bibr" rid="B7-molbank-2010-M700">7</xref>], diuretic [<xref ref-type="bibr" rid="B8-molbank-2010-M700">8</xref>], anti-HIV [<xref ref-type="bibr" rid="B9-molbank-2010-M700">9</xref>] and anticancer [<xref ref-type="bibr" rid="B10-molbank-2010-M700">10</xref>]. Some pyridazinone derivatives like indolidan [<xref ref-type="bibr" rid="B11-molbank-2010-M700">11</xref>], bemoradan [<xref ref-type="bibr" rid="B12-molbank-2010-M700">12</xref>], primobendan [<xref ref-type="bibr" rid="B13-molbank-2010-M700">13</xref>], levosimendan [<xref ref-type="bibr" rid="B14-molbank-2010-M700">14</xref>] are already approved in the clinical market. The current work describes the synthesis of 6-phenyl-2-(4-phenyl-5-thioxo-4,5-dihydro-1<italic>H</italic>-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2<italic>H</italic>)-one (<bold>3</bold>).</p>
      <p>The purity of the compounds was checked by single-spot TLC, and the compounds were characterized on the basis of spectral data (IR, <sup>1</sup>H-NMR, MS) and elemental analysis. Spectral data of the synthesized compound <bold>3</bold> was in full agreement with its proposed structure. The IR spectra revealed NH, CH, C=S, C=O and C=N absorption bands at 3323, 2930, 2368, 1685 and 1607 cm<sup>-1</sup>, respectively. In the <sup>1</sup>H-NMR spectra, the signals of the respective protons of the title compound were verified on the basis of their chemical shifts, multiplicities, and coupling constants. The two triplets at &#x3B4; 2.54 and 2.99 confirmed the presence of methylene protons at C-4 and C-5 position of the pyridazinone ring, respectively. The multiplet at &#x3B4; 7.13&#x2013;7.93 is due to the aromatic protons. The singlet at &#x3B4; 10.78 is due to the hydrogen of the CSNH group. The <sup>13</sup>C-NMR spectrum showed peaks at &#x3B4; 177 and &#x3B4; 186 for a carbonyl carbon and a thioxo carbon. The mass spectrum shows the presence of a peak at <italic>m/z</italic> 350 (M<sup>+</sup> + 1) in accordance with the molecular formula. The elemental analysis results were within &#xB1;0.4% of the theoretical values. The starting material, 6-oxo-3-phenyl-5,6-dihydropyridazine-1(4<italic>H</italic>)-carbo-hydrazide <bold>1</bold> was synthesized based on a literature method [<xref ref-type="bibr" rid="B15-molbank-2010-M700">15</xref>].</p>
	  <sec>
	  <title/>
      <sec>
        <title>Synthesis of 6-phenyl-2-(4-phenyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2H)-one <italic><bold>3</bold></italic></title>
        <p>An ethanolic solution of 6-oxo-3-phenyl-5,6-dihydropyridazine-1(4<italic>H</italic>)-carbohydrazide <bold>1</bold> (0.01 mol) and phenyl isothiocyanate (0.01 mol) was refluxed for 4 h. The contents were concentrated and poured into crushed ice, filtered and dried to give the crude thiosemicarbazide intermediate as 2-[(6-oxo-3-phenyl-5,6-dihydropyridazin-1(4<italic>H</italic>)-yl)carbonyl]-<italic>N</italic>-phenylhydrazinecarbothioamide <bold>2</bold>. The crude thio-semi-carbazide intermediate <bold>2</bold> (0.005 mol) was refluxed in 2M sodium hydroxide solution (20 mL) for 5 h, cooled, poured into water with continuous stirring and filtered to give the final compound <bold>3</bold> as follows: the filtrate on acidification with glacial acetic acid yielded a solid which was recrystallized from ethanol. The purity of compound <bold>3</bold> was checked by TLC, using toluene/ethyl acetate/formic acid (5:4:1) as mobile phase and iodine (I<sub>2</sub>) as visualizing agent. </p>
        <p>Yield: 40%; m.p. 180&#x2013;182 &#xB0;C; R<sub>f</sub> 0.42; white amorphous solid.</p>
        <p>IR (KBr) &#x3C5;<sub>max</sub> (cm<sup>&#x2212;1</sup>): 3323 (NH), 2930 (CH), 2368 (C=S), 1685 (C=O), 1607 (C=N), 1030.</p>
        <p><sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): &#x3B4; 2.54 (t, <italic>J</italic> = 8.7 Hz, 2H, CH<sub>2</sub>), 2.99 (t, <italic>J</italic> = 8.7 Hz, 2H, CH<sub>2</sub>), 7.13&#x2013;7.93 (m, 10H, Ar-H), 10.78 (s, 1H, CSNH). </p>
        <p><sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>): &#x3B4; 27.1, 33.2, 124.5, 125.3, 128.6, 128.8, 129, 130.8, 131.2, 139.4, 154, 155, 155.6, 177 (C=O), 186 (C=S).</p>
        <p>ESI-MS (<italic>m/z</italic>): 349/350 (M<sup>+</sup>/M<sup>+</sup>+1). </p>
        <p>Anal Calcd. for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>OS: C: 61.87; H: 4.33; N: 20.04. Found: C: 61.82; H: 4.22; N: 19.96.</p>
      </sec>
    </sec>
  </body>
  <back>
  <app-group>
    <app id="app1-molbank-2010-M700">
        <title>Supplementary materials</title>
        <supplementary-material id="molbank-2010-M700-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2010-M700-s001-mod.mol">
   <label>Supplementary File 1</label>
</supplementary-material>
        <supplementary-material id="molbank-2010-M700-s002" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2010-M700-s001.mol">
   <label>Supplementary File 2</label>
</supplementary-material>
    </app>
</app-group>
    <ack>
      <title>Acknowledgements</title>
      <p>One of the authors (Ravinesh Mishra) expresses sincere thanks to the University Grant Commission (UGC), New Delhi, India, for the award of Research Fellowship in Science for Meritorious Students (RFSMS). The authors are also thankful to Jamia Hamdard, New Delhi, India for providing facility for the research work.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1-molbank-2010-M700">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coelho</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sotelo</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ravina</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Pyridazine derivatives. Part 33: Sonogashira approaches in the synthesis of 5-substituted-6-phenyl-3(2H)-pyridazinones</article-title>
          <source>Tetrahedron</source>
          <year>2003</year>
          <volume>59</volume>
          <fpage>2477</fpage>
          <lpage>2484</lpage>
          <pub-id pub-id-type="doi">10.1016/S0040-4020(03)00263-1</pub-id>
        </citation>
      </ref>
      <ref id="B2-molbank-2010-M700">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Demirayak</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Karaburun</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Beis</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Some pyrrole substituted aryl pyridazinone and phthalazinone derivatives and their antihypertensive activities</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2004</year>
          <volume>39</volume>
          <fpage>1089</fpage>
          <lpage>1095</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2004.09.005</pub-id>
          <pub-id pub-id-type="pmid">15571871</pub-id>
        </citation>
      </ref>
      <ref id="B3-molbank-2010-M700">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siddiqui</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Mishra</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Shaharyar</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, characterization and antihypertensive activity of pyridazinone derivatives</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>2283</fpage>
          <lpage>2290</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2010.02.003</pub-id>
          <pub-id pub-id-type="pmid">20189270</pub-id>
        </citation>
      </ref>
      <ref id="B4-molbank-2010-M700">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Monge</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Parrado</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Font</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Alvarez</surname>
              <given-names>E.F.</given-names>
            </name>
          </person-group>
          <article-title>Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinotriazino[4,5-a]indole, and related compounds</article-title>
          <source>J. Med. Chem.</source>
          <year>1987</year>
          <volume>30</volume>
          <fpage>1029</fpage>
          <lpage>1035</lpage>
          <pub-id pub-id-type="doi">10.1021/jm00389a012</pub-id>
          <pub-id pub-id-type="pmid">3585901</pub-id>
        </citation>
      </ref>
      <ref id="B5-molbank-2010-M700">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rubat</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Coudert</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Refouvelet</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Tronche</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bastide</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Anticonvulsant activity of 3-oxo-5-substituted benzylidene-6-methyl-(4H)-2-pyridazinylacetamides and 2-pyridazinylacetyl-hydrazides</article-title>
          <source>Chem. Pharm. Bull.</source>
          <year>1990</year>
          <volume>38</volume>
          <fpage>3009</fpage>
          <lpage>3013</lpage>
          <pub-id pub-id-type="doi">10.1248/cpb.38.3009</pub-id>
          <pub-id pub-id-type="pmid">2128224</pub-id>
        </citation>
      </ref>
      <ref id="B6-molbank-2010-M700">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sircar</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Weishaar</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Kobylarz</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Moos</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Bristol</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Cardiotonic agents. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity</article-title>
          <source>J. Med. Chem.</source>
          <year>1987</year>
          <volume>30</volume>
          <fpage>1955</fpage>
          <lpage>1962</lpage>
          <pub-id pub-id-type="pmid">2822926</pub-id>
        </citation>
      </ref>
      <ref id="B7-molbank-2010-M700">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Longo</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Verde</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>M.E.</given-names>
            </name>
          </person-group>
          <article-title>Pyridazine derivatives XIV. Study of the vasorelaxant action of 6-aryl-5-piperidino-3-hydrazinopyridazines in isolated rat thoracic aorta: Comparison with hydralazine</article-title>
          <source>J. Pharm. Sci.</source>
          <year>1993</year>
          <volume>82</volume>
          <fpage>286</fpage>
          <lpage>290</lpage>
        </citation>
      </ref>
      <ref id="B8-molbank-2010-M700">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akahane</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Katayama</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Mitsunaga</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Discovery of 6-oxo-3-(2-phenylpyrazolo[1,5-<italic>a</italic>]pyridin-3-yl)-1(6<italic>H</italic>)-pyridazinebutanoic acid (FK 838): A novel non-xanthine adenosine A<sub>1</sub> receptor antagonist with potent diuretic activity</article-title>
          <source>J. Med. Chem.</source>
          <year>1999</year>
          <volume>42</volume>
          <fpage>779</fpage>
          <lpage>783</lpage>
          <pub-id pub-id-type="doi">10.1021/jm980671w</pub-id>
          <pub-id pub-id-type="pmid">10072675</pub-id>
        </citation>
      </ref>
      <ref id="B9-molbank-2010-M700">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Livermone</surname>
              <given-names>D.G.H.</given-names>
            </name>
            <name>
              <surname>Bethell</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Cammack</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines</article-title>
          <source>J. Med. Chem.</source>
          <year>1993</year>
          <volume>36</volume>
          <fpage>3784</fpage>
          <lpage>3794</lpage>
          <pub-id pub-id-type="doi">10.1021/jm00076a005</pub-id>
        </citation>
      </ref>
      <ref id="B10-molbank-2010-M700">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malinka</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Redzicka</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lozach</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>New derivatives of pyrrolo[3,4-<italic>d</italic>]pyridazinone and their anticancer effects</article-title>
          <source>Il Farmaco</source>
          <year>2004</year>
          <volume>59</volume>
          <fpage>457</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="doi">10.1016/j.farmac.2004.03.002</pub-id>
          <pub-id pub-id-type="pmid">15178308</pub-id>
        </citation>
      </ref>
      <ref id="B11-molbank-2010-M700">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abouzid</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hakeem</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Khalil</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Maklad</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Pyridazinone derivatives: Design, synthesis, and in vitro vasorelaxant activity</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2008</year>
          <volume>16</volume>
          <fpage>382</fpage>
          <lpage>389</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmc.2007.09.031</pub-id>
          <pub-id pub-id-type="pmid">17905589</pub-id>
        </citation>
      </ref>
      <ref id="B12-molbank-2010-M700">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Combs</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Rampulla</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Klaubert</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Tobia</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Falotico</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Haertlein</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>J.B.</given-names>
            </name>
          </person-group>
          <article-title>6-Benzoxazinylpyridazin-3-ones: Potent, long-acting positive inotrope and peripheral vasodilator agents</article-title>
          <source>J. Med. Chem.</source>
          <year>1990</year>
          <volume>22</volume>
          <fpage>380</fpage>
          <lpage>386</lpage>
          <pub-id pub-id-type="doi">10.1021/jm00163a061</pub-id>
        </citation>
      </ref>
      <ref id="B13-molbank-2010-M700">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robertson</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>N.D.</given-names>
            </name>
            <name>
              <surname>Krushinski</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Pollock</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Swartzendruber</surname>
              <given-names>J.K.</given-names>
            </name>
            <name>
              <surname>Hayes</surname>
              <given-names>J.S.</given-names>
            </name>
          </person-group>
          <article-title>Molecular structure of the dihydropyridazinone cardiotonic 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one, a potent inhibitor of cyclic AMP phospho-diesterase</article-title>
          <source>J. Med. Chem.</source>
          <year>1987</year>
          <volume>30</volume>
          <fpage>623</fpage>
          <lpage>627</lpage>
          <pub-id pub-id-type="doi">10.1021/jm00387a007</pub-id>
          <pub-id pub-id-type="pmid">3031290</pub-id>
        </citation>
      </ref>
      <ref id="B14-molbank-2010-M700">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Archan</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Toller</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Levosimendan: current status and future prospects</article-title>
          <source>Curr. Opin. Anesthesiol.</source>
          <year>2008</year>
          <volume>21</volume>
          <fpage>78</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.1097/ACO.0b013e3282f357a5</pub-id>
          <pub-id pub-id-type="pmid">18195615</pub-id>
        </citation>
      </ref>
      <ref id="B15-molbank-2010-M700">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mishra</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Siddiqui</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>6-Oxo-3-phenyl-5,6-dihydropyridazine-1(4<italic>H</italic>)-carbohydrazide</article-title>
          <source>Molbank</source>
          <year>2010</year>
          <volume>2010</volume>
          <fpage>M652</fpage>
          <pub-id pub-id-type="doi">10.3390/M652</pub-id>
        </citation>
      </ref>
    </ref-list>
    <sec sec-type="display-objects">
      <title>Figure</title>
      <fig id="molbank-2010-M700-f001" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Synthetic route to the title compound <bold>3</bold>.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2010-M700-g001.tif"/>
      </fig>
    </sec>
  </back>
</article>
